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Abstract
Phaeochromocytomas and paragangliomas (PPGLs) are highly heterogeneous tumours with
variable catecholamine biochemical phenotypes and diverse hereditary backgrounds. This
analysis of 18 catecholamine-related plasma and urinary biomarkers in 365 patients with PPGLs
and 846 subjects without PPGLs examined how catecholaminemetabolomic profiles are impacted
by hereditary background and relate to variable hormone secretion. Catecholamine secretion was
assessed in a subgroup of 156 patients from whom tumour tissue was available for measurements
of catecholamine contents. Among all analytes, the free catecholamineO-methylated metabolites
measured in plasma showed the largest tumour-related increases relative to the reference group.
Patients with tumours due to multiple endocrine neoplasia type 2 and neurofibromatosis type 1
(NF1) showed similar catecholamine metabolite and secretory profiles to patients with adrenaline-
producing tumoursandnoevident hereditary background.Tumours from these threepatient groups
contained higher contents of catecholamines, but secreted the hormones at lower rates
than tumours that did not contain appreciable adrenaline, the latter including PPGLs due to
von Hippel–Lindau (VHL) and succinate dehydrogenase (SDH) gene mutations. Large increases
of plasma dopamine and its metabolites additionally characterised patients with PPGLs due
to the latter mutations, whereas patients with NF1 were characterised by large increases in
plasma dihydroxyphenylglycol and dihydroxyphenylacetic acid, the deaminated metabolites of
noradrenaline and dopamine. This analysis establishes the utility of comprehensive catecholamine
metabolite profiling for characterising the distinct and highly diverse catecholamine metabolomic
and secretory phenotypes among different groups of patientswith PPGLs. The data further suggest
developmental origins of PPGLs from different populations of chromaffin cell progenitors.
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Introduction
Phaeochromocytomas and paragangliomas (PPGLs)
are heterogeneous tumours with highly variable signs
and symptoms and diverse clinical presentations
(Manger 2009). Much of the heterogeneity is due to
wide-ranging variations in the types and relative
amounts of catecholamines produced by the tumours
and differences in episodic versus continuous hormonal
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secretion (Feldman et al. 1979, Feldman 1981, Ito et al.
1992, Eisenhofer et al. 2001). This in turn appears to
reflect differences in expression of genes regulating
catecholamine biosynthetic and secretory processes
(Isobe et al. 2000, Eisenhofer et al. 2008, Timmers
et al. 2008).
Synthesis of catecholamines is primarily regulated
by the cytoplasmic enzyme, tyrosine hydroxylase,
which converts tyrosine to 3,4-dihydroxyphenylala-
nine (DOPA; Nagatsu & Stjarne 1998). DOPA is then
converted to dopamine, which is translocated from
the cytoplasm into catecholamine storage vesicles.
The presence of dopamine-b hydroxylase within
storage vesicles of noradrenergic nerves and chro-
maffin cells leads to conversion of dopamine to
noradrenaline. In adrenal medullary chromaffin cells,
noradrenaline is metabolised to adrenaline by phenyl-
ethanolamine-N-methyltransferase (PNMT). Since
that enzyme is located in the cytoplasm, production
of adrenaline depends on leakage of noradrenaline
from storage vesicles by a continuous process that is
counterbalanced by the actions of vesicular mono-
amine transporters to return cytoplasmic catechol-
amines back into storage vesicles.
Metabolism of catecholamines occurs by a plethora
of pathways resulting in numerous metabolites, but
primarily first occurs in the same cells where the
catecholamines are synthesised (Eisenhofer et al.
2004b). The presence of monoamine oxidase in
noradrenergic neurons of the central and sympathetic
nervous systems means that most noradrenaline
produced at these sites is deaminated to 3,4-dihydroxy-
phenylglycol (DHPG) following neuronal reuptake or
leakage of the transmitter from storage vesicles into the
neuronal cytoplasm. Additional presence of catechol-
O-methyltransferase within adrenal chromaffin cells
means that the noradrenaline and adrenaline produced
there are respectively metabolised to normetanephrine
and metanephrine. This depends on leakage of the
catecholamines from storage vesicles into the cyto-
plasm. Metabolism of dopamine can also occur by
multiple pathways leading to production of the
deaminated metabolite, dihydroxyphenylacetic acid,
or the O-methylated metabolite, methoxytyramine.
The present analysis utilised a dataset from a large
population of patients, linked to a tumour tissue bank,
to comprehensively characterise the catecholamine
metabolite profiles of patients with PPGLs, and any
relationships of metabolomic signatures to different
catecholamine secretory phenotypes and hereditary
backgrounds. A total of 18 catecholamine-related
plasma and urinary analytes were examined in 365
patients with PPGLs and 846 subjects without PPGLs
who served as a reference group. The primary aim was
to characterise the presence of distinct catecholamine
biochemical and secretory phenotypes among PPGLs
as a basis for future studies exploring the pathogenetic
characteristics and developmental origins of the
tumours from different populations of chromaffin
cell progenitors.
This manuscript is the third in a series utilizing data
from a single cohort of 1211 subjects. Originally, all
manuscripts in the series were compiled as part of a
single article totaling over 12,500 words. That article
was determined to be unsuitable for publication.
Consequently the original article was split into four
separate manuscripts, each focusing on a separate topic
area. All effort has been made to avoid presentation of
duplicate or redundant material in each of the four
manuscripts. The data in the present manuscript are
focused on catecholamine metabolomic and secretory
profiles that are not presented elsewhere.
Subjects and methods
Subjects
The study involved retrospective analysis of data from
1211 subjects, including 365 patients with patho-
logically confirmed PPGLs and 846 subjects without
PPGLs. The latter group was included for comparative
purposes to establish in patients with PPGLs the
relative increases of plasma and urine tumour
biomarkers above normal. Subjects were investigated
under multicentre clinical protocols, based mainly at
the National Institutes of Health (NIH) in Bethesda
(MD, USA), but which also included several European
Centres. The latter included Radboud University
Medical Center (Nijmegen, The Netherlands), the
University of Florence (Florence, Italy), Gothenburg
University Hospital (Gothenburg, Sweden) and
Dresden University Hospital (Dresden, Germany).
Written informed consent was obtained from patients
enrolled into intramural review board-approved studies
at the NIH, which also allowed for collection of patient
samples at offsite centres.
Patients with PPGLs had a mean age of 40 years
(range 6–83 years) at initial diagnosis of tumours and
included 190 males and 175 females (Table 1). Among
these patients, there were 173 patients with clearly
identified hereditary syndromes or gene mutations and
192 patients in whom there was no clearly identified
mutation or evidence of an established hereditary
syndrome. Among the 192 patients with no evidence of
an established hereditary syndrome, gene testing failed
to confirm the presence of mutations of VHL, RET,
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succinate dehydrogenase subunit D (SDHD) or SDH
subunit B (SDHB) genes in genomic DNA available
from 94 patients.
The high proportion of patients with hereditary
syndromes largely reflects disproportionate referral of
those patients to the participating specialist centres.
Among this group, there were 66 patients with von
Hippel–Lindau (VHL) syndrome, 38 patients with
multiple endocrine neoplasia type 2 (MEN 2), 10
patients with neurofibromatosis type 1 (NF1) and
59 patients with mutations of the SDH genes, including
48 patients with mutations of the SDHB gene and 11
patients of the SDHD gene (Table 1). Three of the
38 patients with MEN 2 had the MEN 2B form of
the syndrome.
Adrenal and extra-adrenal locations of tumours were
determined using results of imaging studies and
surgical and pathological records. Most patients with
VHL syndrome, MEN 2 and NF1 had adrenal tumours
(Table 1). In contrast, most patients with mutations of
SDH genes had extra-adrenal tumours, including eight
patients with multifocal tumours at both adrenal and
extra-adrenal locations.
The 846 subjects without PPGLs included 379 males
and 467 females. Subjects had a mean age of 41 years
(range 6–84 years) and included 175 normotensive
volunteers, 94 hypertensive volunteers and 577
patients in whom testing for PPGLs was carried out
and tumours were excluded by previously described
criteria (Lenders et al. 2002). The use of medications
known to cause false-positive elevations of plasma or
urinary catecholamines and metanephrines (e.g. tri-
cyclic antidepressants and phenoxybenzamine) con-
stituted additional exclusion criteria.
Collections of blood, urine and surgical
specimens
Blood samples from all 1211 study participants were
obtained with subjects supine for at least 20 min before
blood collection. Subjects were instructed to fast
and abstain from caffeinated and decaffeinated
beverages overnight and avoid taking acetaminophen
for 5 days before blood sampling. Samples of blood
were transferred into tubes containing heparin as
anticoagulant and immediately placed on ice until
centrifuged (4 8C) to separate the plasma. Plasma
samples were stored at K80 8C until assayed.
Twenty-four hour urine samples were collected from
338 of the 365 patients with PPGLs and 513 of the 847
subjects without tumours. Samples were collected with
hydrochloric or another acid as a preservative, total
urine volume was determined and aliquots were kept at
4 8C until assayed.
Samples of tumour tissue were procured from 156
patients with PPGLs, generally within 1 h of surgical
resection of tumours. The dimensions of tumours were
recorded. Small samples of each tumour (10–50 mg)
were dissected from the mass, frozen on dry ice and
stored atK80 8C. As part of further processing, tissue
samples were weighed frozen and then homogenised in
at least 5 volumes of 0.4 M perchloric acid containing
0.5 mM EDTA. Homogenised samples were centri-
fuged (1500 g for 15 min at 4 8C), and supernatants
were collected and stored atK80 8C until assayed for
catecholamines.
Laboratory analyses
Plasma, urinary and tissue catecholamines (nor-
adrenaline, adrenaline and dopamine) and plasma and
urinary fractionated metanephrines (normetanephrine
and metanephrine) were quantified by liquid chroma-
tography with electrochemical detection. Concen-
trations of catecholamines were determined after
extraction from plasma or perchloric acid tissue
supernatants using alumina adsorption as described
previously (Eisenhofer et al. 1986). The assays of
catecholamines in plasma also included measurements
of three other catechols: DOPA, the precursor of
dopamine and product of the rate-limiting step in
catecholamine biosynthesis; DHPG, a deaminated
Table 1 Characteristics of patients and their tumours according to the presence or absence of an established specific mutation or
hereditary syndrome
Established mutation or hereditary syndrome
No mutation
or syndromeVHL MEN 2 NF1 SDHB SDHD
N 66 38 10 48 11 192
Age (meanGS.D.) 31G17 40G13 42G13 31G15 31G16 47G16
Gender (M/F) 37/29 17/21 6/4 32/16 6/5 92/100
Tumour location (A/E/B)a 58/5/3 38/0/0 9/1/0 2/43/3 1/5/5 149/40/3
aTumour locations indicate adrenal (A), extradrenal (E) or both adrenal and extra-adrenal (B) primary tumours.
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metabolite of noradrenaline and adrenaline produced
principally within sympathetic nerves; and 3,4-di-
hydroxyphenylacetic acid, the deaminated metabolite
of dopamine.
Plasma and urinary fractionated metanephrines
(normetanephrine and metanephrine) were estimated
using different liquid chromatographic methods as
described elsewhere (Lenders et al. 1993, 2002).
The assays in plasma also allowed determination of
methoxytyramine, the O-methylated metabolite of
dopamine. Assays of plasma concentrations of metan-
ephrine, normetanephrine and methoxytyramine were
principally directed to measurements of the free
metabolites (i.e. free metanephrines and methoxy-
tyramine). However, additional measurements of
the much higher concentrations of deconjugated
metanephrines were also carried in 192 and 789
respective subjects with and without PPGLs. These
latter measurements were carried out after incubating
200 ml aliquots of plasma with sulphatase over
30 min for 37 8C and reflect concentrations of
both free and sulphate-conjugated metabolites,
similar to the measurements of urinary fractionated
metanephrines.
Data analyses
Differences in signal strengths of the 18 plasma and
urinary catecholamine-related analytes were assessed
from comparisons of their relative increases in
patients with PPGLs above mean values in the
reference population. The 95% confidence intervals
of values in the reference group were also calculated
for provision of lower and upper limits of normal.
Values from the reference group were used for
comparisons of catecholamine-related analytes in
subgroups of patients with PPGLs, as outlined below.
Patients identified with disease-causing mutations
or hereditary syndromes were divided into five
subgroups (VHL, MEN 2, NF1, SDHB and SDHD)
according to the nature of the syndrome or gene
mutation that was detected. Patients without evidence
of a hereditary syndrome or mutation were divided
into three subgroups according to the noradrenergic,
adrenergic or dopaminergic phenotypes of their
tumours, as based on previous findings relating
tumour tissue contents of the different catechol-
amines to increases in plasma concentrations of their
respective O-methylated metabolites (Eisenhofer
et al. 2005b). For this, tumour-derived increments
of plasma normetanephrine, metanephrine and meth-
oxytyramine were established by subtracting the
concentration of each metabolite in each patient
with a PPGL from the mean concentration in the
reference group. Noradrenergic tumours were defined
as those with predominant increases of only
normetanephrine, accompanied by either normal
plasma concentrations of metanephrine and meth-
oxytyramine (below the upper reference intervals)
or by increases of !5% for metanephrine and 10%
for methoxytyramine relative to the sum of
increments for all three metabolites. Conversely,
adrenergic and dopaminergic tumours were defined
as those characterised by respective increases of
plasma metanephrine and methoxytyramine above
the upper reference intervals and associated incre-
ments, relative to the combined increments of all
three metabolites, of larger than 5% for metanephrine
and 10% for methoxytyramine.
For estimations of tumour-derived catecholamine
secretion into plasma or excretion into urine,
differences in plasma concentrations (nmol/l) or
urinary outputs (mmol/day) of catecholamines in
patients with PPGLs compared with mean values
in the reference population of subjects without
tumours provided estimates of increases in the
amines due to tumours. Rates of catecholamine
secretion from tumours into plasma were estimated
using the formula, SZP!C!1.44, where S is the
rate of catecholamine secretion (mmol/day), P is
the plasma concentration of catecholamines due to
the tumour (nmol/l), C is the circulatory clearance of
catecholamines from plasma (l/min) and where the
value, 1.440, was used to convert secretion rates of
nmol/min to mmol/day, the same units as for urine.
The formula was based on that described elsewhere
(Eisenhofer et al. 2008).
Rates of catecholamine secretion into plasma or
excretion into urine (mmol/day) were divided by
estimates of tumour volume to normalise for
differences in tumour size and to derive final rates in
units of mmol/day per cubic cm of tumour. Volumes of
tumours (V) in cubic cm were estimated using the
formula for the volume of a sphere, VZ4/3 pr3, where
r, the radius in cm, was derived from estimated mean
diameters (the latter was calculated from the cubed
roots of rectangular volumes).
Rate constants for catecholamine secretion into
plasma or excretion into urine (per day) –
representing the proportions of total catecholamines
in a tumour secreted into plasma or excreted into
urine over a day – were estimated by dividing rates
of catecholamine secretion into plasma or excretion
into urine (mmol/day) by total tumour catecholamine
contents (mmol). Total tumour catecholamine con-
tents were estimated from the product of tissue
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catecholamine concentrations and tumour mass (the
latter was derived from tumour volume, assuming a
specific gravity of 1.0).
Statistical analysis
Owing to the skewed distributions of plasma concen-
trations and urinary outputs of catecholamines and
their metabolites, statistical significance of differences
in neurochemical data was determined in all cases after
logarithmic transformation. Comparisons of data
among groups were by ANOVA with the Tukey–
Kramer or Scheffe’s tests used for post hoc compari-
sons. Patients were clustered using an unsupervised
hierarchical clustering method to delineate distinctions
and similarities among different groups of patients.
This analysis utilised sets of analytes that most clearly
differed among groups.
Results
Tumour-related increases in plasma and urine
catecholamines and metabolites
Increases in plasma concentrations and urinary
outputs of the three endogenous catecholamines,
their O-methylated and deaminated metabolites and
their amino acid precursor, DOPA, showed consider-
able variability among the 365 patients with PPGLs
relative to the reference population of 846 subjects
(Fig. 1). Among the principal metabolites of
noradrenaline, DHPG in plasma and VMA in urine
showed the lowest signal strengths in patients with
PPGLs. Plasma-free normetanephrine showed the
highest signal strength among all 18 catechol-related
analytes profiled, with a 12.2-fold increase above the
reference population that significantly (P!0.0004)
surpassed all other analytes, including deconjugated
normetanephrine in plasma (7.4-fold increase) and
urine (6.7-fold increase).
Among the O-methylated metabolites of adrenaline,
there were no differences in signal strengths of
free or deconjugated metanephrine in urine or
plasma, but relative increases of these metabolites
were larger (P!0.05) than those for plasma and
urinary adrenaline (Fig. 1). Among the dopamine-
related analytes, plasma concentrations of free
methoxytyramine showed the largest signal with 3.3-
fold increases above the reference population, sur-
passing (P!0.006) all other dopamine-related ana-
lytes. Plasma DOPA, DOPAC and urinary dopamine
were increased by only 10–38% above mean levels of
the reference population.
Plasma and urine catecholamine
metabolomic profiles
Distinct patterns in the profiles of the 18 catechol-
related analytes emerged after patients with PPGLs
were grouped according to hereditary syndromes or, in
patients without hereditary syndromes, according to
catecholamine phenotype (Table 2). Among the latter
patients, there were 87 patients with predominantly
Plasma NA
Plasma f-NMN
Plasma f-MN
Plasma d-MN
Urine d-MN
Plasma DA
Plasma f-MTY
Plasma d-MTY
Plasma DOPAC
Plasma DOPA
Urine DA
Plasma d-NMN
Plasma DHPG
Urine NA
Urine d-NMN
Urine VMA
Urine A
Plasma A
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0
Fold increase above reference population
Amino acid
Deaminated
metabolites
Deconjugated
O-methylated
metabolites
Plasma free
O-methylated
metabolites
Catecholamines
Figure 1 Plasma and urinary catecholamine metabolomic
profiles in patients with PPGLs relative to reference. Data are
shown as fold increases (meansGS.E.M.) of values in patients
with PPGLs above mean values for the reference population.
Data for the catecholamines, including noradrenaline (NA),
adrenaline (A) and dopamine (DA), are shown by the empty
bars; for the free O-methylated catecholamine metabolites,
including normetanephrine (f-NMN), metanephrine (f-MN) and
methoxytyramine (f-MTY), by the black bars; for the deconju-
gated O-methylated catecholamine metabolites, including
deconjugated normetanephrine (d-NMN), deconjugated meta-
nephrine (d-MN) and deconjugated methoxytyramine (d-MTY),
by the dark grey bars; for the deaminated catecholamine
metabolites, including dihydroxyphenylglycol (DHPG), vanillyl-
mandelic acid (VMA) and dihydroxyphenylacetic acid
(DOPAC), by the medium grey bars; and for the amino acid
precursor of the catecholamines, dihydroxyphenylalanine
(DOPA), by the light grey bar.
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noradrenaline-producing tumours (noradrenergic
phenotype), 95 patients with tumours that produced
significant amounts of adrenaline (adrenergic pheno-
type) and 10 patients with tumours characterised by
significant dopamine production (dopaminergic
phenotype).
The clearest pattern to emerge among patients with
hereditary PPGLs was a divergence in increases of
plasma concentrations and urinary outputs of adrena-
line and its O-methylated metabolite, metanephrine,
measured in both free and deconjugated forms
(Table 2). Specifically, patients with VHL, SDHB and
SDHD mutations showed no significant increases of
plasma or urinary adrenaline and free or deconjugated
metanephrine above reference levels. In contrast,
patients with MEN 2 and NF1 showed highly
significant (P!0.0001) 7- to 31-fold increases of all
adrenaline-related analytes, a pattern similar to that in
patients with adrenergic tumours and no clear
hereditary syndrome.
Unsupervised hierarchical cluster analysis utilising
the plasma and urinary data for adrenaline and its
metabolites identified two dominant expression clus-
ters (Fig. 2). Cluster 1 comprised all patients with VHL
and SDH mutations, whereas cluster 2 comprised MEN
2 and NF1 patients. The remaining patients with no
evidence of an established hereditary syndrome or
gene mutation were partitioned among the two clusters.
Most of those with noradrenergic or dopaminergic
tumours partitioned in cluster 1, whereas most of
those with adrenaline-producing tumours partitioned
in cluster 2.
Patients with NF1 were further distinguished from
MEN 2 patients and other patient groups by higher
(P!0.05) plasma concentrations of DHPG (Table 2).
Plasma concentrations of DOPAC were also higher
(P!0.05) in patients with NF1 than in patients with
MEN 2 and VHL syndrome. Post-operative values
were available in two of the ten patients with NF1.
Both these two subjects showed pre-operative to post-
operative decreases in plasma concentrations of DHPG
(65 and 76% decreases) and DOPAC (32 and 53%
decreases), indicating that the pre-operatively
increased levels of the metabolites were derived from
the tumours.
Larger (P!0.0001) increases of plasma-free
normetanephrine relative to noradrenaline in patients
with adrenergic than noradrenergic or dopaminergic
tumours represented another pattern in neurochemical
profiles (Table 2). More specifically, increases of
plasma normetanephrine above reference were 4.3- to
7.8-fold larger than those of noradrenaline in all
patients with adrenaline-producing tumours, including
those with MEN 2 and NF1. This contrasted with
patients who had noradrenergic or dopaminergic
tumours, including patients with VHL, SDHB and
SDHD mutations, in whom increases in plasma-free
normetanephrine were only 1.8- to 3.0-fold larger than
those of noradrenaline.
Distinctly larger increases of dopamine-related
analytes in patients with tumours due to SDHB
and SDHD mutations compared to other mutations
represented another clear difference in profiles of
catechol-related analytes among patient groups
(Table 2). In particular, plasma concentrations of
dopamine and free methoxytyramine were more than
90-fold higher (P!0.0001) than reference in patients
with SDHB mutations and more than 70-fold higher
(P!0.001) in patients with SDHD mutations. In
contrast, these analytes showed less than fourfold
increases above reference in VHL, MEN 2 and NF1
patients. Also in striking contrast to the more than
70-fold increases in plasma-free methoxytyramine and
dopamine, urinary outputs of dopamine in patients with
SDHB and SDHD mutations were respectively
increased by only 2.9- and 3.3-fold above reference.
Tumour locations and catecholamine
phenotypes
All patients with NF1 and MEN 2 showed increases in
plasma metanephrine that characterised their tumours
as adrenergic, and all except one patient had tumours at
adrenal locations (Table 1). Remarkably, the single
patient with NF1 who had a retroperitoneally located
extra-adrenal tumour also showed substantial increases
in plasma metanephrine (1.74 nmol/l), plasma adrena-
line (1.08 nmol/l) and urinary metanephrine
(7.78 mmol/day).
As indicated by the predominantly adrenal locations
of PPGLs among patients with VHL syndrome
(Table 1), the noradrenergic phenotype of tumours in
these patients was independent of proximity to the
adrenal cortex. Lack of an adrenergic phenotype in
tumours due to SDH mutations was consistent with
their mainly extra-adrenal locations. Nevertheless, 11
of these patients had adrenal tumours with normal
plasma and urinary concentrations of metanephrine in
all except two patients. One patient had a slightly
increased plasma metanephrine (19% above the upper
limit). That patient, however, had a substantially
increased plasma normetanephrine (13-fold above the
upper limit) and a normal urinary output of meta-
nephrine indicating relatively little, if any, tumoural
adrenaline production. The second patient had a
normal plasma concentration of metanephrine, but
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a slightly increased urinary output of metanephrine
(18% increase above the upper limit) and a dramati-
cally increased urinary output of normetanephrine
(32-fold above the upper limit), again indicating
negligible tumoural adrenaline relative to noradrenaline
production.
Among the 87 patients with no hereditary syndrome
who had PPGLs with an adrenergic phenotype, all
except 4 patients had tumours with adrenal locations
(96%). In contrast, among the 95 patients with
noradrenergic PPGLs and the 10 patients with
dopaminergic PPGLs, 62 and 40% respectively had
tumours with exclusively adrenal locations.
Tumour catecholamines and secretory
phenotypes
Tumour tissue concentrations of catecholamines
showed considerable variability among the different
groups of patients with and without established
disease-causing mutations (Fig. 3A). The presence of
markedly higher tumour tissue concentrations of
adrenaline in patients with MEN 2 and NF1 than in
those with mutations of VHL, SDHB and SDHD genes
represented the clearest distinguishing feature among
patients with hereditary PPGLs. Tumour tissue
concentrations of noradrenaline also showed consi-
derable differences among groups, with generally
higher levels in tumours that produced adrenaline
than those that did not. Consequently, total tissue
concentrations of catecholamines (sum of dopamine,
noradrenaline and adrenaline) were highest in adrena-
line-producing tumours, and lowest in all other groups
of tumours, regardless of the presence or absence of a
hereditary syndrome.
Rates of tumour-derived catecholamine secretion
into plasma (Fig. 3B) or excretion into urine (Fig. 3C),
normalised to tumour volume, showed a reciprocal
pattern compared to that for the differences of tumour
tissue catecholamines among the groups (Fig. 3A).
Specifically, while tissue concentrations of catechol-
amines were lowest in tumours with a noradrenergic or
dopaminergic phenotype and highest in those with an
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Figure 2 Unsupervised hierarchical cluster analysis of patients
with and without an established mutation or hereditary
syndrome. Patients with VHL or SDH mutations shown in red
are confined to cluster 1, whereas patients with MEN 2 and NF1
in blue are confined to cluster 2. Patients without evidence of
hereditary syndrome are illustrated in green for those with
adrenaline-producing tumours and in yellow for noradrenergic
or dopaminergic tumours. Clustering was based on measured
values for adrenaline-related analytes in plasma and urine, with
lower to higher analyte levels illustrated in grey scale by
respective progression from lighter to darker heat map areas.
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adrenergic phenotype, the former tumours were
characterised by high rates and the latter by low rates
of catecholamine secretion into plasma or excretion
into urine. Patients with VHL syndrome or with
noradrenergic tumours and no identified hereditary
syndrome showed particularly high rates of tumoural
catecholamine secretion, averaging 5- to 7-fold higher
than in patients with MEN 2 and NF1 or with
adrenergic tumours and no hereditary syndrome.
The differences in tumour-derived catecholamine
secretion and excretion among the different patient
groups were particularly pronounced when assessed as
rate constants for catecholamine secretion into plasma
(Fig. 3D) or excretion into urine (Fig. 3E). The rate
constants for catecholamine secretion into plasma
indicated that adrenaline-producing sporadic and
hereditary tumours released only 2–5% of their tumour
tissue contents of catecholamines into the bloodstream
per day, compared to 57% for sporadic noradrenergic
tumours and 34, 46 and 15% respectively for tumours
from patients with VHL, SDHB and SDHD gene
mutations. Similarly, only between 0.1 and 0.4% of the
catecholamine contents of adrenaline-producing spora-
dic and hereditary tumours were excreted into urine per
day, compared to 3.0% for sporadic noradrenergic
tumours and between 1.2 and 4.9% for tumours from
patients with VHL, SDHB and SDHD gene mutations.
Discussion
This study involving a large cohort of well-charac-
terised patients with PPGLs provides a comprehensive
analysis of relative increases in catecholamines and
catecholamine metabolites in patients with and without
hereditary PPGLs. Our previous observations about
catecholamine phenotypic differences in hereditary
PPGLs were limited to patients with MEN 2 and VHL
syndrome and did not include the comprehensive
analysis of the catecholamine metabolome described
here (Eisenhofer et al. 2001, 2004a, 2005b, 2008,
Huynh et al. 2005, Cleary et al. 2007). Our other
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Figure 3 Bar graphs showing tumour contents of catechol-
amines (panel A), rates of tumour-derived catecholamine
secretion into plasma (panel B) and excretion into urine (panel
C), and rate constants for tumour-derived catecholamine
secretion into plasma (panel D) and excretion into urine (panel
E). Data are shown for tumours from patients with VHL
syndrome (nZ44), MEN 2 (nZ32), NF1 (nZ6) and with
mutations of SDHB (nZ11) and SDHD (nZ3) genes. Data are
also shown for noradrenergic (NA, nZ26) and adrenergic
(A, nZ34) tumours from patients without evidence of an
established hereditary syndrome or gene mutation. Different
alphabetic characters indicate significant differences (P!0.05)
between groups, while the presence of identical characters
indicates lack of a significant difference.
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findings suggesting tumoural production of dopamine
in patients with SDHB mutations did not include
comparisons with other patient groups or measure-
ments of plasma methoxytyramine, tumour tissue
dopamine or measured values for plasma dopamine
(Timmers et al. 2007). The present more comprehen-
sive dataset confirms many of the findings of these
earlier studies, but more importantly considerably
extends previous observations by establishing distinct
catecholamine metabolomic and secretory phenotypes
of PPGLs among multiple subgroups of patients,
including those with tumours due to mutations of
SDHD, SDHB, VHL, NF1 and RET genes. These data
have relevance to emerging concepts concerning the
highly heterogeneous nature of PPGLs, how this
heterogeneity relates to underlying germline mutations
of tumour susceptibility genes and how this in turn
explains distinct differences in gene expression profiles
and pathways of development of tumours from
different chromaffin cell progenitors.
Catecholamine metabolomic profiles explained
The profiling of catecholamine-related analytes in
plasma and urine establishes that among all precursor
amines and metabolites examined, the free O-methyl-
ated metabolites provide higher signal strengths for
indicating the presence of PPGLs than their precursor
catecholamines or corresponding deaminated and
sulphate-conjugated metabolites. The higher signal
strengths of the O-methylated metabolites than of their
monoamine precursors have been amply demonstrated
(Grossman et al. 2006), and are established to reflect
continuous production of O-methylated metabolites
within chromaffin tumour cells by processes that are
independent of variations in exocytotic catecholamine
secretion (Eisenhofer et al. 1998). The particularly low
signal strength of DHPG is in agreement with previous
findings (Brown 1984) and reflects the substantial and
almost exclusive production of this metabolite within
sympathetic nerves (Fig. 4), which considerably dilutes
any additional contribution from chromaffin tumour
cells. Formation of VMA within the liver, mainly after
extraneuronal O-methylation of the DHPG formed
within sympathetic neurons (Eisenhofer et al. 2004b),
explains the relatively low diagnostic signal strength
of this metabolic end product.
The higher diagnostic signal strengths of plasma
free than of plasma and urinary deconjugated nor-
metanephrine and methoxytyramine are also explained
by different sources of the free compared to the
sulphate-conjugated metabolites (Fig. 4). Sulphate
conjugation occurs principally in gastrointestinal
tissues as a mechanism for inactivating both dietary-
derived monoamines and the substantial amounts of
endogenous dopamine and noradrenaline produced by
mesenteric organ catecholamine systems (Eisenhofer
et al. 2004b). The contributions of these sources to
levels of sulphate-conjugated normetanephrine and
methoxytyramine thereby dilute the signals of the
sulphate-conjugated metabolites derived from the free
metabolites produced within chromaffin tumour cells.
Because almost all adrenaline is produced within
adrenal chromaffin cells, there is little influence of
MNMN
Sympathetic
nerves
DHPG NMN
MHPG
VMA
MAO
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ADH
MAO
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Liver
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Adrenal
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Gut
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Circulatory clearance by kidneys
Figure 4 Neuronal, extraneuronal and adrenal pathways
of metabolism for noradrenaline and adrenaline. NA,
noradrenaline; A, adrenaline; DHPG, dihydroxyphenylglycol;
MN, metanephrine; NMN, normetanephrine; MHPG, methox-
yhydroxyphenylglycol; VMA, vanillylmandelic acid; MHPG-SO4,
methoxyhydroxyphenylglycol sulphate; NMN-SO4, normeta-
nephrine sulphate; MN-SO4 metanephrine sulphate;
MAO, monoamine oxidase; COMT, catechol-O-methyl-
transferase; ADH, alcohol dehydrogenase; SULT1A3,
sulfotransferase type 1A3.
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other sources of adrenaline to dilute any diagnostic
signal of sulphate-conjugated metanephrine relative to
its free metanephrine precursor; thus, in contrast to
normetanephrine and methoxytyramine, both free and
deconjugated metanephrine have similar diagnostic
signal strengths. Nevertheless, since most of the signal
strength of the O-methylated metabolites reflects that
of normetanephrine, the free metabolites provide more
sensitive and specific biomarkers for PPGLs compared
to the deconjugated metanephrines (Lenders et al.
2002, Unger et al. 2009). They are also less susceptible
to dietary influences (de Jong et al. 2009).
The much lower signal strength of urinary dopamine
compared to plasma dopamine and plasma-free and
deconjugated methoxytyramine is explained by the
more than 90% of dopamine in urine that is derived
from renal extraction and decarboxylation of circulat-
ing DOPA (Brown & Allison 1981). This large
contribution of plasma DOPA to urinary dopamine
considerably dilutes any signal of tumour-derived
urinary dopamine. Thus, compared to plasma measure-
ments of dopamine and methoxytyramine, measure-
ments of urinary dopamine provide an insensitive
biomarker of tumour dopamine production (Eisenhofer
et al. 2005a).
Catecholamine metabolomic phenotypes
Our observations of distinct patterns in catecholamine
metabolomic profiles among different groups of
patients with hereditary PPGLs extend and bring
together previous isolated observations about different
catecholamine phenotypes and gene expression pro-
files. In particular, the present data showing distinct
catecholamine metabolomic profiles in tumours from
NF1 and MEN 2 patients, compared to patients with
mutations of VHL, SDHB and SDHD genes, are
consistent with patterns in gene expression profiles
observed by two other groups (Dahia et al. 2005,
Favier et al. 2009). Using unsupervised hierarchical
cluster analysis, these groups established the presence
of two dominant expression clusters, one that included
tumours from NF1 and MEN 2 patients and the other
tumours from patients with mutations of VHL, SDHB
and SDHD genes. Similarly, here, we also show the
presence of two dominant clusters comprised of the
same patient groups, but in this instance established
using unsupervised hierarchical cluster analysis of
catecholamine metabolomic profiles.
The differences in gene expression profiles from
the two earlier transcriptomic studies indicated
two pathways of tumourigenesis: one pathway in
VHL-, SDHB- and SDHD-related tumours involved
activation of hypoxia- and angiogenesis-related
genes, and the other pathway in tumours from MEN
2 and NF1 patients involved increased kinase
signalling. The present data additionally suggest
different origins of the two cluster groups from
adrenergic and noradrenergic chromaffin cell precur-
sors, or alternatively, downstream effects of the
differentially activated signalling pathways on
expression of PNMT, the enzyme that converts
noradrenaline to adrenaline.
Interestingly, while tumours in NF1 and MEN 2
patients exhibited similar adrenergic phenotypes, large
increases of both plasma DHPG and DOPAC provided
an additional feature that distinguished tumours in NF1
patients from those of other groups. The substantial
increases of these deaminated metabolites of nor-
adrenaline and dopamine suggest higher activity of
monoamine oxidase and a more neuronal-like meta-
bolising phenotype in NF1-associated tumours than in
other PPGLs.
Furthermore, while tumours in patients with VHL
and SDH mutations all exhibited negligible adrenaline
production, large increases of dopamine and dopa-
mine-related metabolites in patients with SDH
mutations represented an additional characteristic that
distinguished this group from patients with tumours
due to VHL mutations. Thus, while transcriptomic
profiling studies indicate that PPGLs due to SDH and
VHL mutations are closely linked (Dahia et al. 2005),
the present catecholamine metabolomic profiling data
clearly indicate different dopaminergic and nor-
adrenergic neurochemical signatures among the two
groups. These latter findings agree with a more recent
transcriptomic profiling study that confirmed the
presence of two distinct cluster groups, but also
revealed further differences in gene expression
between tumours due to VHL and SDH mutations
(Favier et al. 2009). Other studies have established
contrasting clinical manifestations of SDHB- and
VHL-associated chromaffin cell tumours (Sriranga-
lingam et al. 2009) that may also relate to differences in
catecholamine metabolomic and secretory phenotypes
observed here.
Catecholamine secretory phenotypes
In addition to establishing distinct catecholamine
metabolomic phenotypes, this study also establishes
for the first time that the various groups of patients
develop tumours with distinct catecholamine secretory
phenotypes. More specifically, adrenaline-producing
tumours contain higher concentrations of catechol-
amines yet show lower rates of catecholamine
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secretion into plasma and excretion into urine
compared to tumours that do not produce appreciable
adrenaline.
Differences in secretory characteristics and
expression of secretory pathway components in
different populations of adrenergic and noradrenergic
chromaffin cells are well established (Marley & Livett
1987, Teraoka et al. 1993, Langley & Grant 1995,
Aunis & Langley 1999). In particular, fractionation of
bovine adrenal medullary cells into two populations of
low density noradrenergic and high density adrenergic
chromaffin cells revealed that the noradrenergic cells
released a higher percentage of their catecholamine
contents than adrenergic cells (Krause et al. 1996).
Similarly in the present study, noradrenergic tumours
released between 15 and 57% of their catecholamine
stores each day, compared to !5% for adrenaline-
producing tumours.
The divergent lower tissue concentrations but higher
rates of catecholamine secretion in noradrenergic than
adrenergic PPGLs extend findings of previous studies
focusing on tumours in MEN 2 and VHL syndrome
(Eisenhofer et al. 2001, 2008). These earlier studies
showed that although tumours in VHL syndrome
secrete noradrenaline at higher more continuous rates
than those in patients with MEN 2, the latter tumours
are more easily provoked to secrete catecholamines in
episodic bursts with a resulting more symptomatic
clinical presentation. These differences in secretory
profiles reflect extensive differences in expression of
numerous genes encoding components of the regulated
secretory pathway, including enzymes regulating
transmitter synthesis, vesicular proteins and their
processing enzymes, exocytotic machinery com-
ponents as well as receptors and other signal
transduction factors responsible for excitation-
secretion coupling (Eisenhofer et al. 2008). In general,
noradrenergic tumours due to VHL mutations are
characterised by immature constitutive secretory
pathways, whereas mature regulated secretory
pathways typical of fully differentiated adrenal
medullary chromaffin cells characterise adrenergic
tumours in MEN 2.
Similar differences in expression of secretory
pathway components also likely extend to and explain
the differences in tumour tissue contents and secretion
of catecholamines among the various groups of
patients of this study. The lower rates of catecholamine
secretion from adrenergic than noradrenergic or
dopaminergic tumours furthermore clarify other
differences in the clinical presentation of the different
groups. In particular, the larger relative increases of
plasma normetanephrine than noradrenaline in patients
with adrenaline-producing tumours than other groups
reflect the lower rates of hormonal secretion in the
former than latter groups. This also explains the
strikingly much higher diagnostic sensitivity of
metanephrines than catecholamines for detection of
adrenaline- than noradrenaline-producing PPGLs
(Eisenhofer et al. 2005b).
Perspective
The adrenergic phenotype of phaeochromocytomas in
patients with MEN 2 and NF1 largely reflects their
origins from adrenal chromaffin cells in which PNMT
has been induced by exposure to high local concen-
trations of adrenal cortical steroids. Relative lack of
adrenaline production in most extra-adrenal tumours
similarly reflects their lack of proximity to adrenal
sources of steroids. What remains unexplained is the
relative lack of adrenaline production in a significant
proportion of adrenal tumours, including all those in
patients with VHL and SDH mutations.
Unlike the adrenal medulla of some animal species
that contain separate populations of adrenergic and
noradrenergic chromaffin cells, the adult human
adrenal medulla is largely comprised of a single
population of PNMT-positive adrenergic cells (Cleary
et al. 2005). This observation argues against the
development of phenotypically distinct adrenal
phaeochromocytomas from separate populations of
mature adrenergic and noradrenergic or dopaminergic
chromaffin cells. Dedifferentiation provides another
explanation. However, an alternative basis for the
distinct phenotypes of PPGLs is suggested by the
current view that some of the tumours develop from
immature chromaffin cell progenitors that have
escaped neuronal apoptosis during embryonic develop-
ment (Lee et al. 2005, Dahia 2006, Tischler 2006,
Woodward & Maher 2006).
Of relevance to the above alternative explanation,
PPGLs with a noradrenergic phenotype overexpress
the gene for hypoxia-inducible transcription factor
2a (HIF-2a; Eisenhofer et al. 2004a), a transcription
factor with a central role in the development of
PPGLs in patients with VHL and SDH mutations
(Pollard et al. 2006, Favier et al. 2009). Of further
relevance, an increasing body of evidence indicates
that expression of HIF-2a and related genes is
crucial for the development of embryonic tyrosine
hydroxylase expressing sympathoadrenal progenitor
cells (Tian et al. 1998, Favier et al. 1999, Bishop et al.
2008, Brown et al. 2009). Blocking this expression
leads to impaired development of these cells and
reduced catecholamine synthesis, presumably through
G Eisenhofer et al.: Phaeochromocytoma catecholamine phenotypes
www.endocrinology-journals.org108
increased apoptosis of tyrosine hydroxylase expressing
noradrenaline-producing chromaffin cells.
The above observations conversely also explain
susceptibility of immature chromaffin progenitor cells
to the tumourigenic influences of mutations that further
increase expression of HIF-2a. In such exposed
progenitor cells, failure of developmental culling and
arrested differentiation may be expected to lead to the
development of PPGLs with a retained immature
dopaminergic or noradrenergic catecholamine pheno-
type at both extra-adrenal and adrenal locations.
In contrast, tumours with a mature adrenergic
phenotype would only be expected to develop after
migration of neural crest chromaffin progenitors into
the adrenal enlagen, and then only after induction of
PNMT by locally produced steroids (Adams &
Bronner-Fraser 2009). This concept is also consistent
with other findings that adrenaline-producing tumours
present at later ages than noradrenergic PPGLs
(Eisenhofer et al. 2011).
In summary, previous findings of global differences
in gene expression profiles among different groups of
hereditary and sporadic PPGLs and the present
findings of associated patterns in catecholamine
metabolomic and secretory profiles together support
the likelihood that many of the differences between
the various groups of tumours reflect distinct
origins from immature noradrenergic or dopaminergic
chromaffin progenitors compared to the more highly
differentiated adrenergic chromaffin cells of the adult
adrenal medulla. The distinct catecholamine metabo-
lomic and secretory signatures of different groups of
PPGLs provide a new framework for future studies
exploring the pathogenetic development of these
tumours from different populations of chromaffin
cell progenitors.
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